(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...
KT-621 offers a potential once-daily oral alternative to injectable biologics for patients with asthma driven by Type 2 inflammation. The Food and Drug Administration (FDA) has granted Fast Track ...
Nurix Therapeutics secures a $15 million license extension from Sanofi for its STAT6 program, totaling $127 million to date. Nurix Therapeutics announced that Sanofi has exercised its option to ...
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that ...
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that the company has nominated a ...
STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results